More Post from the Author
- Climate Activists Exploit Jasper Wildfire Anniversary - ICJ did no Due Diligence says Friends of Science Society
- Broadridge Schedules Webcast and Conference Call to Review Fourth Quarter and Fiscal Year 2025 Results on August 5, 2025
- AveriSource announces availability of AI-Powered Modernization Platform in the new AWS Marketplace AI Agents and Tools category
- OysterLink Reports Surge in Controversial Restaurant Fee Talks
- PRIVACY ALERT: House of Dior Under Investigation for Data Breach of Customer Records
Indivior Statement RE: Delayed FDA Approval of SUBLOCADE Label Changes
Published on Wed 12 Feb 2025 8:07:04 UTC

RICHMOND, Va., Feb. 12, 2025 /PRNewswire/ --Indivior PLC (Nasdaq/LSE: INDV)provides the following update regarding its PDUFA action date for label changes (rapid initiation protocol and alternative injection sites) for SUBLOCADE (buprenorphine extended-release) Injection, which was scheduled for February 7, 2025:
Yesterday, February 11th, the FDA informed Indivior that, following acceptance of the proposed label for SUBLOCADE, there were no outstanding items to address, but that final review of the SUBLOCADE label changes has been delayed.
Indivior will provide further updates on the status of the approval of the proposed SUBLOCADE label changes as appropriate.
SOURCE Indivior PLC

More Post from the Author
- Climate Activists Exploit Jasper Wildfire Anniversary - ICJ did no Due Diligence says Friends of Science Society
- Broadridge Schedules Webcast and Conference Call to Review Fourth Quarter and Fiscal Year 2025 Results on August 5, 2025
- AveriSource announces availability of AI-Powered Modernization Platform in the new AWS Marketplace AI Agents and Tools category
- OysterLink Reports Surge in Controversial Restaurant Fee Talks
- PRIVACY ALERT: House of Dior Under Investigation for Data Breach of Customer Records